GlassScriptPhysician profile
Balbir S Minhas
NPI 1033158779
$7,782.60
in general payments reported to CMS, 2019-2025
15 companies · $20.94 in 2025
The $20.94 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,992 · 2020: $164 · 2021: $336 · 2022: $110 · 2023: $160 · 2025: $20.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $180.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,774.81 | 2019 | |
| Abbvie INC. | $379.21 | 2019-2022 | |
| Amgen INC. | $119.96 | 2023 | Amjevita |
| Braintree Laboratories, INC. | $76.70 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.48 | 2021 | |
| Merck Sharp & Dohme LLC | $56.51 | 2021-2023 | Dificid |
| Cook Medical LLC | $54.52 | 2019-2020 | |
| Medtronic, INC. | $53.99 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.41 | 2019-2020 | |
| Redhill Biopharma INC. | $40.17 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $32.30 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $21.68 | 2019 | |
| Intra-Sana Laboratories | $20.94 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.44 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $16.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Balbir Minhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.